Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Mata

Showing results (81-90 of 144) with videos related to

Pageof 15
Sort By:
Clinical Chemistry|May 14, 2005
Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemiaDiego Tejedor, Sergio Castillo, Pilar Mozas, et al.
Human Biology|April 7, 2006
Screening of APOB gene mutations in subjects with clinical diagnosis of familial hypercholesterolemiaErardo Meriño-Ibarra, Sergio Castillo, Pilar Mozas, et al.
Personalized Medicine|May 2, 2018
Multivariate analysis for coronary heart disease in heterozygote familial hypercholesterolemia patientsJuan Francisco Sánchez Muñoz-Torrero, Maria D Rivas, Jose Zamorano, et al.
European Journal of Preventive Cardiology|October 4, 2025
External validation of the SAFEHEART risk-equation for predicting cardiovascular events in Australian patients with familial hypercholesterolaemiaMaría Elena Mansilla-Rodríguez, Manuel Jesús Romero-Jiménez, Jing Pang, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|January 9, 2017
Plasma PCSK9 measurement by liquid chromatography-Tandem mass spectrometry and comparison with conventional ELISAMikaël Croyal, Fanta Fall, Michel Krempf, et al.
Atherosclerosis|September 6, 2016
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemiaRodrigo Alonso, Pedro Mata, Ovidio Muñiz, et al.
BMJ Open|March 29, 2023
Risk factors for cardiovascular events in patients with heterozygous familial hypercholesterolaemia: protocol for a systematic reviewMaría Elena Mansilla-Rodríguez, Manuel J Romero-Jimenez, Alina Rigabert Sánchez-Junco, et al.
Lipids in Health and Disease|April 12, 2011
R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control studyJuan Criado-García, Francisco Fuentes, Cristina Cruz-Teno, et al.
Atherosclerosis|May 18, 2019
Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemiaLeopoldo Pérez de Isla, Kausik K Ray, Gerald F Watts, et al.
Journal of the American College of Cardiology|March 18, 2014
Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutationRodrigo Alonso, Eduardo Andres, Nelva Mata, et al.
Pageof 15

Showing results (81-90 of 144) with videos related to

Sort By:
Pageof 15
Clinical Chemistry|May 14, 2005
Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemiaDiego Tejedor, Sergio Castillo, Pilar Mozas, et al.
Human Biology|April 7, 2006
Screening of APOB gene mutations in subjects with clinical diagnosis of familial hypercholesterolemiaErardo Meriño-Ibarra, Sergio Castillo, Pilar Mozas, et al.
Personalized Medicine|May 2, 2018
Multivariate analysis for coronary heart disease in heterozygote familial hypercholesterolemia patientsJuan Francisco Sánchez Muñoz-Torrero, Maria D Rivas, Jose Zamorano, et al.
European Journal of Preventive Cardiology|October 4, 2025
External validation of the SAFEHEART risk-equation for predicting cardiovascular events in Australian patients with familial hypercholesterolaemiaMaría Elena Mansilla-Rodríguez, Manuel Jesús Romero-Jiménez, Jing Pang, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|January 9, 2017
Plasma PCSK9 measurement by liquid chromatography-Tandem mass spectrometry and comparison with conventional ELISAMikaël Croyal, Fanta Fall, Michel Krempf, et al.
Atherosclerosis|September 6, 2016
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemiaRodrigo Alonso, Pedro Mata, Ovidio Muñiz, et al.
BMJ Open|March 29, 2023
Risk factors for cardiovascular events in patients with heterozygous familial hypercholesterolaemia: protocol for a systematic reviewMaría Elena Mansilla-Rodríguez, Manuel J Romero-Jimenez, Alina Rigabert Sánchez-Junco, et al.
Lipids in Health and Disease|April 12, 2011
R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control studyJuan Criado-García, Francisco Fuentes, Cristina Cruz-Teno, et al.
Atherosclerosis|May 18, 2019
Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemiaLeopoldo Pérez de Isla, Kausik K Ray, Gerald F Watts, et al.
Journal of the American College of Cardiology|March 18, 2014
Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutationRodrigo Alonso, Eduardo Andres, Nelva Mata, et al.
Pageof 15